HAEMONETICS CORP — Director's Dealing 2022

Sep 21, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2022-09-19

Reporting Person: Basil Michelle L (EVP and General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-19	Common Stock	M	3464	$38.43	Acquired	38859	Direct
2022-09-19	Common Stock	M	4213	$41.64	Acquired	43072	Direct
2022-09-19	Common Stock	M	1011	$56.57	Acquired	44083	Direct
2022-09-19	Common Stock	S	11448	$78.36	Disposed	32635	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-19	Non-qualified Stock Option (Right to Buy)	$38.43	M	3464	Disposed	2024-03-06	Common Stock (3464)	Direct
2022-09-19	Non-qualified Stock Option (Right to Buy)	$41.64	M	4213	Disposed	2024-06-06	Common Stock (4213)	Direct
2022-09-19	Non-qualified Stock Option (Right to Buy)	$56.57	M	1011	Disposed	2028-05-18	Common Stock (1011)	Direct

Footnotes

F1: Transaction pursuant to an existing 10b5-1 trading plan.

F2: This number includes unvested restricted stock units ("RSUs") previously reported.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.75, inclusive. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F4: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.